Xarelto (rivaroxaban) / J&J 
Welcome,         Profile    Billing    Logout  
 97 Diseases   247 Trials   247 Trials   14602 News 


«12...1617181920212223242526...170171»
  • ||||||||||  rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg.
    Journal:  Increased menstrual bleeding among direct oral anticoagulant users (Pubmed Central) -  May 14, 2023   
    Anticoagulants can cause severe menstrual bleeding, especially in women with a history of heavy menstrual periods. The type of anticoagulant can be changed and the bleeding can be treated by both hormonal and non-hormonal therapies.
  • ||||||||||  rivaroxaban / Generic mfg., apixaban / Generic mfg.
    Clinical impact of switching or continuation of apixaban or rivaroxaban among patients with non-valvular atrial fibrillation (Station 9) -  May 13, 2023 - Abstract #ESC2023ESC_1108;    
    Off-label underdosed rivaroxaban 10mg was associated with a higher risk of thromboembolism but a lower risk of major bleeding, while off-label overdosed rivaroxaban 20mg was associated with worse outcome in most clinical events. Bleeding outcomes associated with switching or continuation of apixaban or rivaroxaban in NVAF patients were consistent with existing evidence supporting a better safety profile for apixaban vs rivaroxaban.
  • ||||||||||  rivaroxaban / Generic mfg., warfarin / Generic mfg., apixaban / Generic mfg.
    Safety and effectiveness of initial high-dose anticoagulation therapy for cancer-associated venous thromboembolism in the real world: insight from the COMMAND VTE Registry-2 (Station 10) -  May 13, 2023 - Abstract #ESC2023ESC_1066;    
    Of patients with initial high-dose anticoagulation therapy, rivaroxaban and apixaban were administered in 210 and 134 patients, respectively, whereas, of those without, direct oral anticoagulant (DOAC), warfarin and other therapies were administered in 855, 164 and 144 patients, respectively. In the real-world clinical practice, initial high-dose anticoagulation therapy for cancer-associated VTE seemed to be more frequently administered for low bleeding-risk patients and did not show a higher risk of bleeding including gastrointestinal bleeding.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Development and validation of the DOAC Score: a novel bleeding risk prediction tool for patients with atrial fibrillation (Stockholm) -  May 13, 2023 - Abstract #ESC2023ESC_152;    
    Current clinical decision tools for assessing bleeding risk have limited performance and were developed for individuals anticoagulated with warfarin...We then refined the model in the GARFIELD-AF registry, with individuals taking dabigatran, edoxaban, rivaroxaban, and apixaban... In individuals with AF on DOAC therapy, the DOAC Score can help stratify patients based on expected bleeding risk.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    PK/PD data, Review, Journal:  Pharmacokinetic drug-drug interactions with direct anticoagulants in the management of cancer-associated thrombosis. (Pubmed Central) -  May 12, 2023   
    Hence, here we have provided a framework to allow clinicians to better deal with pharmacokinetic drug-drug interactions between DOACs and cancer therapies in the management of cancer-associated thrombosis. In this review we have discussed the current literature, how the pharmacokinetic profile links to the label information on DDI, and have provided a practical proposal, applied to a clinical case.
  • ||||||||||  rivaroxaban / Generic mfg.
    Trial completion date, Trial primary completion date:  CAPITAL-RAPTOR: Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion (clinicaltrials.gov) -  May 12, 2023   
    P3,  N=1800, Recruiting, 
    In this review we have discussed the current literature, how the pharmacokinetic profile links to the label information on DDI, and have provided a practical proposal, applied to a clinical case. Trial completion date: Aug 2023 --> Jun 2026 | Trial primary completion date: Dec 2022 --> Dec 2025
  • ||||||||||  FEATURES OF POLYCYTHEMIA VERA WITH THE JAK 2 EXON 12 MUTATION. () -  May 12, 2023 - Abstract #EHA2023EHA_3068;    
    Mouse models have demonstrated the ability of JAK2 exon 12 mutations to induce a MPN phenotype with prominent erythrocytosis. This is consistent with the results of our study on a small group of patients.